Fig. 2From: Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureOverall survival of treated secondary AML by treatment approach and karyotype risk. (A) Adverse risk karyotype and (B) non-adverse risk karyotypeBack to article page